Moving the Goalpost Toward Remission: The Case for Combination Immunomodulatory Therapies in Psoriatic Arthritis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Moving the Goalpost Toward Remission: The Case for Combination Immunomodulatory Therapies in Psoriatic Arthritis

Published:2021-07-28 Issue:9 Volume:73 Page:1574-1578
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Scher Jose U.¹^ORCID,Ogdie Alexis²,Merola Joseph F.³,Ritchlin Christopher⁴^ORCID

Affiliation:

1. New York University School of Medicine and NYU Langone Orthopedic Hospital New York New York

2. University of Pennsylvania Perelman School of Medicine Philadelphia

3. Brigham and Women’s Hospital and Harvard Medical School Boston Massachusetts

4. University of Rochester School of Medicine and Dentistry Rochester New York

Funder

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.41765

Reference31 articles.

1. Psoriatic arthritis

2. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

3. Psoriatic Arthritis

4. American college of rheumatology preliminary definition of improvement in rheumatoid arthritis

5. Strategies to Improve Outcomes in Psoriatic Arthritis

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Racial and ethnic determinants of psoriatic arthritis phenotypes and disease activity;Rheumatology;2024-02-01

2. Risankizumab for the treatment of active psoriatic arthritis in adults;Expert Review of Clinical Immunology;2023-10-03

3. Kombinasjonsbehandling med biologiske og andre avanserte legemidler;Tidsskrift for Den norske legeforening;2023-10-03

4. Investigational monoclonal antibodies in early development for psoriatic arthritis: beyond the biosimilars;Expert Opinion on Investigational Drugs;2023-08-03

5. Expert Perspective: Management of the Psoriatic Arthritis Patient After Failure of One Tumor Necrosis Factor Inhibitor;Arthritis & Rheumatology;2023-05-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3